Clinical Trials

HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

NCT07175220 2025-11-18

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Phase 2 Recruiting

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07102901 2025-09-10

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Phase 2 Recruiting

351 enrolled

Stomach Neoplasms

NCT05149807 2025-08-20

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Phase 2/3 Terminated

81 enrolled

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

NCT05179239 2025-04-15

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Phase 3 Terminated

31 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04624217 2024-01-11

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Phase 1/2 Completed

56 enrolled

Pancreatic Neoplasms

NCT04699968 2023-06-07

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04580498 2023-05-19

A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

Phase 2 Unknown

107 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04324814 2023-02-21

A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Phase 1 Completed

41 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03774979 2022-11-08

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Phase 1/2 Not yet recruiting

193 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05503888 2022-08-17

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

160 enrolled

Recurrence

NCT05198817 2022-06-28

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

240 enrolled

Advanced Malignant Tumors

NCT04679038 2022-01-26

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

222 enrolled

Other solid neoplasm

Solid Tumor

NCT04282070 2021-12-21

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

91 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05132413 2021-11-24

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Phase 3 Unknown

561 enrolled

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer

NCT03710265 2021-11-22

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

206 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04650633 2021-10-29

SHR-1701 in Patients With Recurrent/Metastatic Scchn

Phase 2 Unknown

130 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05020925 2021-08-25

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1/2 Unknown

30 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04884009 2021-05-12

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Phase 2 Unknown

106 enrolled